Study of A3309 in Patients With Dyslipidemia

Summary

The purpose of this trial is to determine the efficacy and safety of A3309 administered to patients with dyslipidemia (high cholesterol levels).

Timeline

Start

2010-02

Primary completion

2010-09

Completion

2010-09

Outcome

Met primary endpoint

paper In the dyslipidemia study LDL cholesterol was reduced by 7.4 % (p = 0.044) PMID 26197999 ↗

Publications

• Rudling M, Camilleri M, Graffner H, Holst JJ, Rikner L. Specific inhibition of bile acid transport alters plasma lipids and GLP-1. BMC Cardiovasc Disord. 2015 Jul 22;15:75. doi: 10.1186/s12872-015-0070-9.

Drugs

Indications